SCHEMBL310575

SCHEMBL310575

COc1cc(N2CCC(N3CCN(S(C)(=O)=O)CC3)CC2)ccc1Nc1nccc(-c2c(-c3ccc(OC)c(C(=O)Nc4c(F)cccc4F)c3)nc3ccccn23)n1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 12/20 0.88
INSR P06213 8/20 0.88
EGFR P00533 7/20 0.88
ERBB2 P04626 7/20 0.88
MAPK14 Q16539 3/20 0.88
AURKA O14965 2/20 0.88
LCK P06239 2/20 0.88
AURKB Q96GD4 2/20 0.88
BRAF P15056 1/20 0.88
ERBB4 Q15303 1/20 0.88
IKBKB O14920 1/20 0.82
CHUK O15111 1/20 0.82
RPS6KA4 O75676 1/20 0.82
PAK3 O75914 1/20 0.82
ABL1 P00519 1/20 0.82
NTRK1 P04629 1/20 0.82
FYN P06241 1/20 0.82
FES P07332 1/20 0.82
HCK P08631 1/20 0.82
FGFR1 P11362 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310555 0.97 EGFR (0.85) IGF1RINSREGFRERBB2MAPK14
SCHEMBL310472 0.97 IGF1R (0.84) IGF1RINSREGFRERBB2MAPK14
SCHEMBL310328 0.96 IGF1R (0.85) IGF1RINSREGFRERBB2MAPK14
SCHEMBL310382 0.95 EGFR (0.86) IGF1RINSREGFRERBB2MAPK14
SCHEMBL310884 0.94 EGFR (0.88) IGF1RINSREGFRERBB2MAPK14
SCHEMBL310539 0.94 EGFR (0.78) IGF1RINSREGFRERBB2MAPK14
SCHEMBL310310 0.93 IGF1R (1.00) IGF1RINSREGFRERBB2MAPK14
SCHEMBL310409 0.93 EGFR (0.87) IGF1RINSREGFRERBB2MAPK14
SCHEMBL310768 0.92 EGFR (0.84) IGF1RINSREGFRERBB2MAPK14
SCHEMBL310244 0.92 EGFR (0.88) IGF1RINSREGFRERBB2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 IGF1R 633/4885INSR 814/4885EGFR 491/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 IGF1R 633/4885INSR 814/4885EGFR 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.